High inherited risk predicts age-associated increases in fibrosis in patients with MASLD

Gastrointestinal Cancer

Traditional serrated adenomas associated with risk of subsequent high-risk polyps and colorectal cancer

Am J Gastroenterol

Chen Y, Polychronidis G, Zhang Y, Shen J, Lu Y, Du M, Song M

doi: 10.14309/ajg.0000000000003588

Gastrointestinal CancerHepatology

Non-invasive risk-based surveillance of hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease

Gut

Lai JC, Yang B, Lee HW, Lin H, Tsochatzis EA, Petta S, Bugianesi E, Yoneda M, Zheng MH, Hagström H, Boursier J, Calleja JL, Goh GB, Chan WK, Gallego-Duràn R, Sanyal AJ, de Lédinghen V, Newsome PN, Fan JG, Castera L, Lai M, Fournier-Poizat C, Wong GL, Pennisi G, Armandi A, Nakajima A, Liu WY, Shang Y, Saint-Loup M, Llop E, Teh KKJ, Lara-Romero C, Asgharpour A, Mahgoub S, Chan MS, Canivet CM, Romero-Gómez M, Kim SU, Wong VW, Yip TC

doi: 10.1136/gutjnl-2025-334981

Further Publications

Cardiovascular risk assessment tools are insufficient for patients with metabolic dysfunction associated steatotic liver disease

Am J Gastroenterol

Barritt AS 4th, Tapper EB, Newsome PN, Gazis D, Morris H, Mospan AR, Perez AD, Kim Y, Neuschwander-Tetri BA, Loomba R, Sanyal A, TARGET-NASH Investigators

doi: 10.14309/ajg.0000000000003595

HepatologyFurther Publications

GLP-1 Receptor Agonists and Risk for Cirrhosis and Related Complications in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease

JAMA Intern Med

Kanwal F, Kramer JR, Li L, Yang YX, Cao Y, Yu X, Samuel R, Ali B, Desiderio R, Cholankeril G, Bajaj M, El-Serag HB, Asch SM

doi: 10.1001/jamainternmed.2024.4661

Gastrointestinal Cancer

Reliable Performance of mALBI Grade-Based Risk Models for Predicting the Prognosis of Patients With Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab as First-Line Treatment: Comparative Analysis of 13 Risk Models

J Gastroenterol Hepatol

Hatanaka T, Kakizaki S, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Toyoda H, Ogawa C, Nishikawa H, Nishimura T, Kawata K, Kosaka H, Naganuma A, Yata Y, Ohama H, Kuroda H, Matono T, Tanaka K, Tada F, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Kumada T, Real‐life Practice Experts for HCC (RELPEC) Study Group, and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)

doi: 10.1111/jgh.16871

Hepatology

Effectiveness of a model of care based on Fibrosis-4 and liver stiffness measurement for the screening of patients with type 2 diabetes mellitus at risk of advanced liver disease: results from an Italian prospective multicentre study

Am J Gastroenterol

Caviglia GP, Ferro A, D'Ambrosio R, Perbellini R, Lampertico P, Periti G, Valenti L, Ciccioli C, Pennisi G, Petta S, Brodosi L, Petroni ML, Marchignoli F, Pironi L, Sagripanti A, Argenziano ME, Svegliati-Baroni G, Rosso C, Barutta F, Armandi A, Gruden G, Bugianesi E

doi: 10.14309/ajg.0000000000003493

Hepatology

Development and Validation of a Noninvasive Model for the Detection of High-Risk Varices in Patients with Unresectable HCC

Clin Gastroenterol Hepatol

Parikh ND, Jones P, Salgia R, Bhan I, Grinspan LT, Jou JH, Zhou K, Jalal P, Roccaro G, Rangnekar AS, Benhammou JN, Pillai A, Mehta N, Wedd J, Yang JD, Kim AK, Duarte-Rojo A, Oloruntoba OO, Tevar A, Au JS, Blain Y, Rao S, Catalano OA, Lewis S, Mendiratta-Lala M, King K, Sachdev L, Lee EW, Bruno J, Kamel I, Tolosa C, Kao K, Badawi T, Przybyszewski EM, Quirk L, Nathani P, Haydel B, Leven E, Wong N, Albertian R, Chen A, Aloor FZ, Mohamed IB, Elkheshen A, Marvil C, Issac G, Clinton JW, Woo SM, Yum J, Rieger E, Hutchison AL, Turner DA, Alsudaney M, Hernandez P, Xu Z, Khalid A, Barrick B, Wang B, Tapper EB, Hao W, Singal AG

doi: 10.1016/j.cgh.2024.07.008

Gastrointestinal CancerHepatology

Older age but not comorbidity is associated with worse survival in patients with hepatocellular carcinoma

Clin Gastroenterol Hepatol

Kanneganti M, Al-Hasan M, Bourque S, Deodhar S, Yang JD, Huang DQ, Kulkarni AV, Gopal P, Parikh ND, Kanwal F, Patel MS, Singal AG

doi: 10.1016/j.cgh.2024.10.015

Hepatology

Metabolic dysfunction-associated steatotic liver disease, metabolic alcohol-related liver disease, and incident dementia: a nationwide cohort study : MASLD, MetALD, and dementia risk

BMC Gastroenterol

Shin WY, Kang ES, Oh YH, Sha M, Xia Q, Jeong S, Cho Y

doi: 10.1186/s12876-025-03814-1

Related content

Traditional serrated adenomas associated with risk of subsequent high-risk polyps and colorectal cancer

Non-invasive risk-based surveillance of hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease

Cardiovascular risk assessment tools are insufficient for patients with metabolic dysfunction associated steatotic liver disease

GLP-1 Receptor Agonists and Risk for Cirrhosis and Related Complications in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease

Reliable Performance of mALBI Grade-Based Risk Models for Predicting the Prognosis of Patients With Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab as First-Line Treatment: Comparative Analysis of 13 Risk Models

Effectiveness of a model of care based on Fibrosis-4 and liver stiffness measurement for the screening of patients with type 2 diabetes mellitus at risk of advanced liver disease: results from an Italian prospective multicentre study

Development and Validation of a Noninvasive Model for the Detection of High-Risk Varices in Patients with Unresectable HCC

Older age but not comorbidity is associated with worse survival in patients with hepatocellular carcinoma

Metabolic dysfunction-associated steatotic liver disease, metabolic alcohol-related liver disease, and incident dementia: a nationwide cohort study : MASLD, MetALD, and dementia risk